Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650685 | 0.93 | NPC1 (0.48) | NPC1RAB9AESR1UBE2NMCHR1 | |
| SCHEMBL5650538 | 0.90 | PPARG (0.49) | NPC1RAB9AESR1UBE2NMCHR1 | |
| SCHEMBL5653629 | 0.85 | NPC1 (0.49) | NPC1RAB9AESR1UBE2NMCHR1 | |
| SCHEMBL5648611 | 0.80 | NPC1 (0.54) | NPC1RAB9AESR1MCHR1LTA4H | |
| SCHEMBL5648873 | 0.79 | PDE6D (0.41) | NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL5652540 | 0.79 | HPGD (0.52) | KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5652071 | 0.78 | HTT (0.51) | RAB9AKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5650705 | 0.77 | KMT2A (0.43) | RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5653711 | 0.76 | LMNA (0.48) | KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5648374 | 0.75 | MAPT (0.41) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | NPC1 1606/4885RAB9A 3641/4885ESR1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.